Clinical Trials
33 trialsXL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Emory University
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
IIT Sutent
Medstar Health Research Institute
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)